"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A study to find out more about cabazitaxel for prostate cancer that has spread and is no longer responding to hormone therapy (GenCab)
This study was done to find out more about how cabazitaxel works for men whose prostate cancer has spread and is no longer responding to hormone therapy.
More about this trial
Doctors can use hormone therapy or a chemotherapy drug called docetaxel to treat prostate cancer that has spread. When this trial started they could then use a chemotherapy drug called cabazitaxel (Jevtana) if the cancer continued to grow.
We already knew from research that cabazitaxel could help men who have already been treated with hormone therapy and docetaxel. But it works better for some men than others.
In this study, researchers took blood samples and samples of prostate tissue (biopsies) from men who were having cabazitaxel. The aim of the study was to look at the genes in the cells and find out more about how cabazitaxel works.
Summary of results
- PSA gene went down in all 3 men
- AR gene went down in 2 men and up in 1 man
- AR-V7 gene went down in 1 man and up in 2 men
- beta-tubulin III gene went down in 2 men and up in 1 man
- AKT1 gene went down in 1 man, up in 1 man and stayed the same in 1 man
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Rakesh Heer
Dr Ian Pedley
Dr Emma Clark
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040